Search clinical trials for: CD20 ,Follicular Lymphoma,Marginal Zone Lymphoma,MIL62

Total 11680 results

Chiron Corporation

Terminated

Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin Lymphoma

United States
Northwestern University
Robert H. Lurie Cancer Center

Terminated

Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL

Non-Hodgkin's Lymphoma (NHL)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | CD20 Positive | Refractory Mantle Cell Lymphoma | Blastoid Variant Mantle Cell Lymphoma | CCND1 Protein Overexpression | CD5 Positive | FCER2 Negative | Pleomorphic Variant Mantle Cell Lymphoma | t(11;14)(q13;q32)

United States
Chinese PLA General Hospital

Recruiting

IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.

Inert Non Hodgkin's Lymphoma

China
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Regeneron Pharmaceuticals

Active, not recruiting

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies (ELM-1)

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma

United States, United Kingdom, Israel, Germany, France
ImmunityBio, Inc.

Withdrawn

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Non Hodgkin Lymphoma
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation

Completed

Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab

Mantle Cell Lymphoma | Lymphocytic Leukemia

United States
Hoffmann-La Roche
Nordic Lymphoma Group

Completed

A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Lymphoma

Sweden, Denmark, Norway
JHL Biotech, Inc.

Terminated

A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients

B Cell Lymphoma

China
Hoffmann-La Roche

Completed

A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma (GAUDI)

Non-Hodgkin's Lymphoma

Spain, France, United Kingdom, Germany, Australia, Italy
Stanford University

Completed

Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma

Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large Cell Lymphoma | Transformed Lymphoma | Other Subtypes of B-cell Lymphoma

United States
Genentech, Inc.
Roche Pharma AG

Terminated

A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM) (FILM)

Rheumatoid Arthritis
University of Rochester

Terminated

Draining PLN and Synovial Inflammation in RA Knee Joints Pre and Post Anti-TNF or B Cell Depletion Therapy

Rheumatoid Arthritis

United States
National Health Research Institutes, Taiwan
National Taiwan University Hospital; Mackay Memorial Hospital; Buddhist Tzu Chi... and other collaborators

Completed

A Phase II Study of Nasal NK/T-cell Lymphoma

Lymphoma

Taiwan
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma
M.D. Anderson Cancer Center
CureTech Ltd

Completed

Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma

Lymphoma

United States
University of Washington
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma

United States
Emory University
Novartis

Terminated

Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Jonsson Comprehensive Cancer Center
Parker Institute for Cancer Immunotherapy

Recruiting

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | CD20 Positive | Refractory Mantle Cell Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Refractory... and other conditions

United States
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Worldwide Clinical Trials

Suspended

Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

B-cell Non-Hodgkin's Lymphoma

United States
Genzyme, a Sanofi Company

Terminated

Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL

Non-Hodgkin's Lymphoma

United States
Mentrik Biotech, LLC

Unknown

Phase I Study of Subcutaneous Ocaratuzumab in Patients With Previously Treated CD20+ B-Cell Malignancies

Previously Treated CD20+ B-cell Malignancies

United States
Shanghai Henlius Biotech

Completed

A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas

B-cell Lymphomas
Larry Saltzman, MD

Suspended

The Leukemia and Lymphoma Society (LLS) T-cells in Blood Cancer and COVID-19 (LLST-Cells)

Covid-19

United States
Rong Tao

Completed

Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL Patients

Extranodal NK-T-Cell Lymphoma, Nasal Type

China
Weill Medical College of Cornell University

Completed

Polymorphisms at Distinct Genetic Loci Affect Response to Anti-CD20 Monoclonal Antibody Therapies

Lymphoma

United States
Dana-Farber Cancer Institute
American Society of Hematology

Recruiting

UPLYFT For Lymphoma Survivors

Lymphoma | Survivorship

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

Diffuse, Large B-Cell, Lymphoma

China
University Health Network, Toronto
Hoffmann-La Roche; Ozmosis Research Inc.

Completed

Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin's

Canada
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of RO7227166 in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin

United States, Belgium, Australia, Denmark, Italy, Spain, France, United Kingdom
Shanghai Public Health Clinical Center

Unknown

The Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma

To Evaluate the Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma
Ranjana Advani
Genentech, Inc.

Completed

Rituximab in Treating Patients With Hodgkin's Lymphoma

Lymphoma | Hodgkin Lymphoma (Category) | Nodular Lymphocyte Predominant Hodgkin Lymphoma

United States
Washington University School of Medicine
Genentech, Inc.

Recruiting

Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed B-Cell Lymphoma | Follicular Lymphoma Grade 3B

United States
Sumithira Vasu
National Cancer Institute (NCI)

Recruiting

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent High Grade... and other conditions

United States
Genentech, Inc.
Roche Pharma AG

Terminated

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT) (SCRIPT)

Rheumatoid Arthritis

United States, Belgium, Canada, Hungary, Argentina, Germany, Spain, Brazil, Poland, Israel, Mexico, Japan, France, Peru, Switzerland, Sweden, Italy, Australia, New Zealand, Panama, Czechia, Netherlands, Slovakia, Slovenia, Taiwan
National Cancer Institute (NCI)

Completed

Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

Chronic Lymphocytic Leukemia | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Fred Hutchinson Cancer Center
Mustang Bio

Active, not recruiting

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic... and other conditions

United States
Soligenix

Recruiting

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

Cutaneous T-Cell Lymphoma/Mycosis Fungoides

United States
Samsung Medical Center

Completed

Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma (DLBCL)

Korea, Republic of
ERYtech Pharma
Centre Leon Berard

Completed

Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia (GRASPALL)

Acute Lymphoblastic Leukemia

France
Lymphoma and Leukemia Society

Recruiting

The Leukemia and Lymphoma Society (LLS) National Research Registry

Blood Cancer

United States
Lymphoma and Leukemia Society

Completed

The Lymphoma and Leukemia Society Amended COVID-19 Registry

Covid19

United States
Ruijin Hospital

Recruiting

A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma

Lymphoma | DLBCL | T Cell Lymphoma

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

A Clinical Study of MIL62 in Primary Membranous Nephropathy

Primary Membranous Nephropathy

China
Ruijin Hospital

Completed

Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

China
Genentech, Inc.
Roche Pharma AG

Terminated

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE) (STAGE)

Rheumatoid Arthritis

United States
Hoffmann-La Roche
Fondazione Italiana Linfomi ONLUS

Terminated

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Diffuse Large B-Cell Lymphoma

Italy, China, Korea, Republic of, Canada, Australia, United States, Austria, Brazil, Denmark, Panama, Peru, Spain, Colombia, United Kingdom, Switzerland, Thailand, Mexico, Taiwan, Hong Kong, Russian Federation, Hungary, Japan, Germany, South Africa and more
Genentech, Inc.
Amgen

Terminated

A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas

Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States

Search clinical trials for: CD20 ,Follicular Lymphoma,Marginal Zone Lymphoma,MIL62

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations